PensionDanmark Pensionsforsikringsaktieselskab Sells 7,017 Shares of Becton, Dickinson and Company $BDX

PensionDanmark Pensionsforsikringsaktieselskab trimmed its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.0% in the second quarter, Holdings Channel.com reports. The firm owned 70,781 shares of the medical instruments supplier’s stock after selling 7,017 shares during the quarter. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Becton, Dickinson and Company were worth $10,711,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Imprint Wealth LLC bought a new stake in shares of Becton, Dickinson and Company during the third quarter worth $25,000. Steph & Co. lifted its stake in shares of Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 65 shares during the last quarter. SHP Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at $26,000. Meeder Asset Management Inc. boosted its holdings in shares of Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares in the last quarter. Finally, Main Street Group LTD bought a new stake in Becton, Dickinson and Company during the 1st quarter worth $29,000. Institutional investors own 86.97% of the company’s stock.

Key Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Quarterly results beat estimates. Fiscal Q3 revenue rose 5.4% year over year to approximately $5.0 billion, exceeding the $4.89 billion consensus estimate. Adjusted EPS of $3.23 also surpassed expectations of $3.14, with growth across BD’s core medical and interventional businesses. BD Reports Third Quarter Fiscal 2026 Financial Results
• Positive Sentiment: BD raised its fiscal 2026 outlook. The company now expects adjusted EPS of $12.62 to $12.72, above the prior outlook and the roughly $12.56 analyst consensus. Management also expects revenue growth toward the high end of its range and is targeting 90% free-cash-flow conversion. Year-to-date operating cash flow increased 33.3% to $2.1 billion, while free cash flow rose 44.6% to $1.7 billion. BD raises FY 2026 adjusted EPS guidance
• Positive Sentiment: Citigroup became more bullish. Citi raised its price target from $198 to $204 and assigned a “buy” rating, implying meaningful upside based on the cited reference price.
• Neutral Sentiment: Analyst views remain divided. Piper Sandler lifted its target to $175 but maintained a “neutral” rating, while Wells Fargo raised its target to $170 and kept an “equal weight” rating. Both targets remain below the cited share price, limiting the positive impact of the revisions.
• Negative Sentiment: Margins and earnings comparisons are concerns. Although revenue and adjusted earnings beat forecasts, margins declined and adjusted EPS fell from $3.68 in the year-earlier quarter. The stock’s elevated valuation may also make investors more sensitive to profitability pressure.

Insider Activity at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 5,189 shares of company stock valued at $765,661. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.3%

Shares of BDX opened at $176.53 on Friday. The stock’s 50-day moving average price is $154.37 and its two-hundred day moving average price is $162.51. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The company has a market capitalization of $48.64 billion, a PE ratio of 53.17, a PEG ratio of 12.53 and a beta of 0.19. The company has a current ratio of 0.87, a quick ratio of 0.55 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the prior year, the firm posted $3.68 earnings per share. The business’s quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts anticipate that Becton, Dickinson and Company will post 12.62 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.

Analyst Ratings Changes

BDX has been the subject of several research reports. UBS Group started coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 target price for the company. Jefferies Financial Group restated a “buy” rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a report on Thursday. The Goldman Sachs Group lowered their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. TD Cowen raised their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday. Finally, Piper Sandler boosted their target price on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $185.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.